<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>18</patient-age><report-id>PHHY2012CA003830</report-id><gender>female</gender><reactions><reaction>Experienced 1 menstruation period within the last year</reaction><reaction>Increased number of lesions</reaction><reaction>Pain upon injection thighs and buttocks / Painful burning injection/ Intense pain</reaction><reaction>Pinpoint bruises at injection sites</reaction><reaction>Nausea</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>EXTAVIA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Relapsing-remitting multiple sclerosis</indication></indications><outcomes/><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053171_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134151</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012CA003830</safetyreportid>
		<primarysourcecountry>CA</primarysourcecountry>
		<occurcountry>CA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-01-10</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CA003830</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>KB</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19930826</patientbirthdate>
			<patientweight>61.224</patientweight>
			<patientheight>140</patientheight>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Experienced 1 menstruation period within the last year</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Oligomenorrhoea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Oligomenorrhoea</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Increased number of lesions</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Brain lesion</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Central nervous system lesion</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pain upon injection thighs and buttocks / Painful burning injection/ Intense pain</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site pain</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Pinpoint bruises at injection sites</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site bruising</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site haematoma</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Nausea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Nausea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Nausea</reactionmeddrapt>
				<reactionfirsttime>134</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testname>Nuclear magnetic resonance imaging</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EXTAVIA</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>BLA 125290</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>8</drugstructuredosagenumb>
				<drugstructuredosageunit code="027"/>
				<drugdosagetext>8 MIU, QOD</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution For Injection</drugdosageform>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Relapsing-remitting multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-11-29</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INTERFERON BETA-1B</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Central nervous system lesion</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Central nervous system lesion</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haematoma</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haematoma</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oligomenorrhoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Oligomenorrhoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CA003830, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a consumer received on 10 Jan 2012 via <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>Extracare Marketing Program and follow up report received from a consumer on 20 Jan 2012. Follow up report from a consumer (patient) received on 10 Apr 2012 via <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>Extracare marketing program. Follow up report received from a consumer (patient's father) on 14 Oct 2012 and follow up report from quality complaint department (QA) received on 06 Dec 2012. This is also a quality complaint report (#CAPC12-00704 / 568686). This report refers to an 18-year old female patient (ID EA000170). The patient's medical history and concomitant medications were not reported. The patient received <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>(<Semaphore x="735118" class="Medicine" value="interferon beta-1b" score="0.74" ID="281308"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.49" ID="268564">interferon beta </Semaphore>1b</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="3115890" class="MedDRA LLT" value="Multiple sclerosis relapse" score="1.00" ID="10048393"><Semaphore x="2451967" class="Disease or Finding" value="Recurrent Disease, Distant Site" score="1.00" ID="C55073">relapsing </Semaphore>remitting <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis </Semaphore></Semaphore>from 29 Nov 2011 at a dose of 8 MIU, every other day, subcutaneous. On an unknown date, after starting the suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>the patient experienced (during the last two or three <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injections </Semaphore>of the <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>) <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>upon <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore>on <Semaphore x="2612811" class="AnatomicStructure" value="Thigh" score="1.00" ID="C33763">thighs </Semaphore>and <Semaphore x="1653419" class="AnatomicStructure" value="Buttock" score="1.00" ID="C89806">buttocks </Semaphore>that lasted about 1 hour. The patient also reported pinpoint <Semaphore x="1650938" class="Disease or Finding" value="Bruise" score="1.00" ID="C37921">bruises </Semaphore>at <Semaphore x="3040169" class="MedDRA LLT" value="Injection site pain" score="1.00" ID="10022086"><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection <Semaphore x="3040169" class="MedDRA LLT" value="Injection site pain" score="1.00" ID="10022086">sites </Semaphore></Semaphore>
     <Semaphore x="3040169" class="MedDRA LLT" value="Injection site pain" score="1.00" ID="10022086">and painful burning </Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection </Semaphore></Semaphore>that used to be <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore><Semaphore x="1882188" class="Disease or Finding" value="Empty Sella Syndrome" score="1.00" ID="C84686">free</Semaphore>. During the follow up call, the patient reported that when she injected in her <Semaphore x="2612811" class="AnatomicStructure" value="Thigh" score="1.00" ID="C33763">thighs</Semaphore>, she <Semaphore x="2005619" class="Procedure" value="Have Pain" score="1.00" ID="C91126">had an intense <Semaphore x="3166801" class="MedDRA LLT" value="Pain in extremity" score="1.00" ID="10033425">pain </Semaphore></Semaphore>
    <Semaphore x="3166801" class="MedDRA LLT" value="Pain in extremity" score="1.00" ID="10033425">in the <Semaphore x="2612811" class="AnatomicStructure" value="Thigh" score="1.00" ID="C33763">thigh </Semaphore></Semaphore>that lasted about one minute and was strong enough to cause her <Semaphore x="2262749" class="Disease or Finding" value="Nausea" score="1.00" ID="C3258">nausea</Semaphore>. The patient experienced 1 <Semaphore x="2217952" class="Disease or Finding" value="Menstruation" score="1.00" ID="C3232">menstruation </Semaphore>period within the last year and wonder if the medication can influence. The reporter also wondered how long it may take before that he could see that the medication was working, since her daughter's last <Semaphore x="2149241" class="Procedure" value="Magnetic Resonance Imaging" score="1.00" ID="C16809">MRI </Semaphore>showed increased number of <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions</Semaphore>. From the QA department it was reported that a <Semaphore x="2472135" class="AnatomicStructure" value="Root" score="1.00" ID="C33446">root </Semaphore>cause could not be determined, as no batch number was provided in the complaint to allow a <Semaphore x="2472135" class="AnatomicStructure" value="Root" score="1.00" ID="C33446">root </Semaphore>cause <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigation</Semaphore>. <Semaphore x="1675087" class="Disease or Finding" value="Cant" score="1.00" ID="C82117">Based </Semaphore>on the absence of potency‐related deviations, and stability data confirming no changes or trend in potency, it was unlikely that there was a technical <Semaphore x="187403" class="Medicine" value="Basis" score="0.49" ID="189629">basis </Semaphore>for the complaint. Without a known lot number or receipt of sample, a more complete <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>could not be completed. As no lot number or sample has been provided, a comprehensive <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>of <Semaphore x="2453473" class="Disease or Finding" value="Recurrent Malignant Neoplasm" score="1.00" ID="C4813">recurrence </Semaphore>could not be determined. Furthermore, a query of AQWA indicated there had been no potency related out of specification results/deviations in the past two years, and a Sep 2012 review of stability data indicated no trends or changes in potency. No corrective or preventive action was indicated. <Semaphore x="1675087" class="Disease or Finding" value="Cant" score="1.00" ID="C82117">Based </Semaphore>on the <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>of the <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigation</Semaphore>, QA department considered the complaint to be not justified. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>for the event pinpoint <Semaphore x="1650938" class="Disease or Finding" value="Bruise" score="1.00" ID="C37921">bruises </Semaphore>at <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="3040617" class="MedDRA LLT" value="Injection" score="1.00" ID="10052995">injection </Semaphore>sites </Semaphore>was condition improving. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>for remaining events was not reported. Seriousness and causality were not reported.Follow up report received from a consumer on 20 Jan 2012: Updated event information.Follow up report from a consumer (patient) received on 10 Apr 2012 via <Semaphore x="561072" class="Medicine" value="Extavia" score="0.93" ID="290629">Extavia </Semaphore>Extracare marketing program. Updated new event (<Semaphore x="2262749" class="Disease or Finding" value="Nausea" score="1.00" ID="C3258">nausea</Semaphore>).Follow up report received from a consumer (patient's father) on 14 Oct 2012. New events (Increased number of <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions </Semaphore>- One <Semaphore x="2217952" class="Disease or Finding" value="Menstruation" score="1.00" ID="C3232">menstruation </Semaphore>period within the last year) were added.Follow up report from quality complaint department received on 06 Dec 2012: Updated <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigation </Semaphore>summary.</narrativeincludeclinical>
				<sendercomment>MAC: Review of available reported data does not allow for a proper causality assessment. </sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>